

Mohammad Madjid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5104775/publications.pdf>

Version: 2024-02-01

18
papers

4,789
citations

840776

11
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

10705
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	2.8	2,392
2	Potential Effects of Coronaviruses on the Cardiovascular System. <i>JAMA Cardiology</i> , 2020, 5, 831.	6.1	1,469
3	The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. <i>Cardiovascular Pathology</i> , 2020, 48, 107233.	1.6	331
4	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	3.4	206
5	Influenza and Cardiovascular Disease. <i>Circulation</i> , 2003, 108, 2730-2736.	1.6	152
6	Regional, Artery-Specific Thresholds of Quantitative Myocardial Perfusion by PET Associated with Reduced Myocardial Infarction and Death After Revascularization in Stable Coronary Artery Disease. <i>Journal of Nuclear Medicine</i> , 2019, 60, 410-417.	5.0	83
7	Effect of High Influenza Activity on Risk of Ventricular Arrhythmias Requiring Therapy in Patients With Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators. <i>American Journal of Cardiology</i> , 2019, 124, 44-50.	1.6	42
8	Mortality Prediction by Quantitative PET Perfusion Expressed as Coronary Flow Capacity With and Without Revascularization. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1020-1034.	5.3	41
9	Applying the Lessons of Influenza to COVID-19 During a Time of Uncertainty. <i>Circulation</i> , 2020, 141, 1667-1669.	1.6	16
10	Quantitative myocardial perfusion positron emission tomography and caffeine revisited with new insights on major adverse cardiovascular events and coronary flow capacity. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 751-762.	1.2	15
11	Complications in Patients With COVID-19â€”Reply. <i>JAMA Cardiology</i> , 2021, 6, 360.	6.1	12
12	Combined LDL and VLDL Electronegativity Correlates with Coronary Heart Disease Risk in Asymptomatic Individuals. <i>Journal of Clinical Medicine</i> , 2019, 8, 1193.	2.4	10
13	Trends and Impact of the Use of Mechanical Circulatory Support for Cardiogenic Shock Secondary to Takotsubo Cardiomyopathy. <i>American Journal of Cardiology</i> , 2021, 139, 28-33.	1.6	8
14	High prevalence of cholesterol-rich atherosclerotic lesions in ancient mummies: A near-infrared spectroscopy study. <i>American Heart Journal</i> , 2019, 216, 113-116.	2.7	6
15	Improvement of left ventricular function with surgical revascularization in patients eligible for implantable cardioverter-defibrillator. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 244-251.	1.7	3
16	Design and rationale of the randomized trial of comprehensive lifestyle modification, optimal pharmacological treatment and utilizing PET imaging for quantifying and managing stable coronary artery disease (the CENTURY study). <i>American Heart Journal</i> , 2021, 237, 135-146.	2.7	2
17	An attempt to reconcile the contrasting results of analyses on implantable cardioverter-defibrillator shocks during the pandemic. <i>European Heart Journal</i> , 2021, , .	2.2	1
18	Highlights of late-breaking clinical trials from the 2005 Scientific Sessions of the American Heart Association. <i>Future Cardiology</i> , 2006, 2, 161-164.	1.2	0